Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2017

View Archived Issues

PepVax initiates in vivo efficacy study for lead candidate PVX-009

Heptares initiates phase I study of selective muscarinic M4 receptor agonist HTL-0016878

Oncodesign acquires Bertin Pharma's pharmaceutical and biotech services business

EMD Serono details discovery of BTK inhibitor now in clinical development

Second-generation RET inhibitors developed for irritable bowel syndrome

EMBL, Savira patent compounds for treating influenza

MediWound reports new phase II data on EscharEx

Inventisbio describes new indoleamine 2,3-dioxygenase 1 inhibitors

High mobility group protein B1 inhibitors disclosed by Kyungpook National University

Global Blood Therapeutics divulges novel EHMT2 inhibitors

Sprint Bioscience discloses novel PIK3C3 and autophagy inhibitors

Protein kinase inhibitors reported at Korea Institute of Science and Technology, DGMIF

Debiopharm, Evotec describe new IDH1, IDH2 inhibitors

APRIL has prognostic significance in acute heart failure

Midatech submits CTA to begin first-in-human study of MTD-201

Spyryx Biosciences initiates phase II study of SPX-101 in cystic fibrosis

INN-108 receives U.S. orphan drug status for pediatric ulcerative colitis

U.S. Traumakine BLA submission can follow completion of European and Japanese phase III studies

FDA grants tentative approval to Sanofi's Admelog

FDA confers orphan drug status on VXM-01 for malignant glioma

Venetoclax given FDA orphan drug designation for mantle cell lymphoma

Collaboration discovers enhanced GABA(A) receptor subunit alpha-6 ligands

FDA approves Mylotarg for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.